Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00427583

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Malignant Peripheral Nerve Sheath Tumors Clinical Trial

Official title:
An Open-label Multicenter Phase II Study of Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Clinical Trial Summary

This study assesses the safety and efficacy of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00427583
Study type Interventional
Source Novartis
Contact
Status Terminated
Phase Phase 2/Phase 3
Start date May 2006
View Details
See also
  Status Clinical Trial Phase
Completed NCT01661283 - SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Phase 2
Completed NCT03433183 - SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Phase 2
Active, not recruiting NCT02584647 - PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Phase 1/Phase 2
Withdrawn NCT03880123 - Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Phase 1
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Recruiting NCT05245500 - Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion Phase 1/Phase 2
Recruiting NCT03618381 - EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Phase 1
Active, not recruiting NCT03989596 - Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Phase 2
Recruiting NCT04897321 - B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Phase 1
Active, not recruiting NCT04483778 - B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Phase 1
Not yet recruiting NCT06277154 - MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma Phase 2
Active, not recruiting NCT03651375 - Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Phase 2
Recruiting NCT03611868 - A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05985161 - A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors Phase 2
Recruiting NCT03141021 - Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors